sorafeniblenvatinibnivolumabipilimumabNIVOSORIPILEN
… trial assessing nivolumab plus ipilimumab versus lenvatinib or sorafenib for unresectable hepatocellular carcinoma in the first-line set…
20articles mentioning drugs
51drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Lenvatinib ×
Lenvatinib
This drug is selected. Its supporting articles are shown below.
Articles mentioning Lenvatinib
20 articles · page 2 of 2lenvatinibsorafenibAtezolizumab-Bevacizumabhepatocellular carcinomatertiary hospital
…41% ECOG 1 (n=18). Previous treatments were sorafenib (n=3) and lenvatinib (n=2).The median number of cycles received was 10 (4-54). The r…
sorafeniblenvatinibMASLD-HCCMetabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC)first-line therapy
…y of CD133-siRNA nanoparticles potently sensitised MASLD-HCC to sorafenib and lenvatinib, significantly improving outcomes in MASLD-HCC.C…
sorafeniblenvatinibnivolumabatezolizumabHepatocellular carcinomaHCCtyrosine kinase inhibitors
…e very limited. For decades, tyrosine kinase inhibitors such as sorafenib and lenvatinib have been the only first-line treatments for adv…
nivolumabpembrolizumabatezolizumabipilimumabtremelimumabdurvalumabavelumablenvatinibTACEMelanoma+3 more
…nicalTrials.gov between 2014 and 2024 evaluating approved ICIs (nivolumab, pembrolizumab, atezolizumab, durvalumab, avelumab, ipilimumab,…
nivolumabpembrolizumabcabozantiniblenvatinibipilimumabaxitinibmccRCCICI rechallenge
…an age was 63.8 years. The most common first-line regimens were nivolumab (N) + cabozantinib (44.1%), N + ipilimumab (26.5%), pembrolizum…
lenvatinibsorafenibatezolizumab-bevacizumabpembrolizumabProton-TKIProton radiotherapyLinkou Chang Gung Memorial Hospitalhepatocellular carcinomaHCCProton-TKI
…mbrolizumab (n = 5). Tyrosine kinase inhibitors (TKIs) included lenvatinib (n = 16) and sorafenib (n = 13).Results With a median follow-up…
cabozantiniblenvatinibdabrafenibosteosarcomasolid tumoursmalignancies
…) had lung metastases. The most frequently prescribed TKIs were cabozantinib (n=31), dabrafenib (n=25), and lenvatinib (n=17). 48% of patien…